We are developing “single enzyme activity-based liquid biopsy”
for early detection of diseases and drug development support.
Research Achievements Towards Company Founding Published in Cell Reports Methods
Cosomil and Takeda Commence Collaboration on Enzyme Activity Biomarker Measurement
Pre-Series A Funding to Accelerate R&D of Cancer Early Detection Blood Test
Our Technology Earns Breakthrough Award Division of Medicinal Chemistry 2023
We are developing high-precision liquid-based diagnostic technology using "single enzyme activity-based protein profiling (SEAP),"
to evaluate the activity of enzymes in the blood molecule at single protein level.
Our business focuses on 2 main areas: early disease diagnosis and support for drug development.
For example, by utilizing our "single enzyme activity-based protein profiling (SEAP)" technology, pancreatic cancer may be detected in its early stage.
We will contribute to future growth of healthcare
by applying fluorescent enzyme substrates and microdevices.